FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023161457> ?p ?o ?g. }

• W2023161457 endingPage "1184" @default.
• W2023161457 startingPage "1177" @default.
• W2023161457 abstract "The CURE study demonstrated the benefit of clopidogrel in patients with non–ST elevation (NSTE) acute coronary syndromes (ACSs), including those undergoing percutaneous coronary intervention (PCI). It did not report the relation between clopidogrel and timing of PCI or, more specifically, the role of clopidogrel in patients managed with an early interventional strategy, the current preferred treatment option for patients with NSTE ACSs. In the present study, we examined the relation between clopidogrel therapy, timing of PCI, and cardiovascular (CV) events in patients participating in the CURE study. A total of 12 562 patients with NSTE ACSs was randomized in double-blind fashion to clopidogrel or placebo (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year. We analyzed the data of the 2658 CURE patients undergoing PCI and related the incidence of outcome events (CV death/myocardial infarction [MI]) to timing of PCI after randomization: early (<48 hours, median 1.0 day, n = 370), intermediate (≥48 hours to initial hospital discharge, median 6.8 days, n = 1360), and late (after initial hospital discharge, median 47.6 days, n = 928). Clopidogrel showed consistent treatment benefit over the 12-month (mean 9 months) follow-up period irrespective of timing of PCI (relative risk [RR] 0.53 for the early group, RR 0.72 for the intermediate group, RR 0.70 for the late group). After adjustment for propensity to undergo PCI, the greatest treatment benefit of clopidogrel was observed in patients undergoing PCI <48 hours after randomization (RR 0.45, 95% CI 0.21-0.96, P = .038), although with overlap between groups. The lowest absolute event rate (6.7% CV death/MI) was observed in patients treated with clopidogrel and undergoing PCI within 48 hours. There was no increased risk of major bleeding in the early PCI group. The benefit of therapy with clopidogrel in addition to aspirin in patients presenting with NSTE ACSs was significant irrespective of the timing of PCI. The combination of clopidogrel and an early (<48 hours) interventional strategy was associated with low absolute event rates for CV death/nonfatal MI." @default.
• W2023161457 created "2016-06-24" @default.
• W2023161457 creator A5002556684 @default.
• W2023161457 creator A5007198463 @default.
• W2023161457 creator A5017244982 @default.
• W2023161457 creator A5018419311 @default.
• W2023161457 creator A5019968582 @default.
• W2023161457 creator A5039466154 @default.
• W2023161457 creator A5041291525 @default.
• W2023161457 creator A5047779930 @default.
• W2023161457 creator A5057167171 @default.
• W2023161457 date "2005-12-01" @default.
• W2023161457 modified "2023-10-17" @default.
• W2023161457 title "Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study" @default.
• W2023161457 cites W1552261360 @default.
• W2023161457 cites W1553345686 @default.
• W2023161457 cites W189220612 @default.
• W2023161457 cites W1987027612 @default.
• W2023161457 cites W1988665858 @default.
• W2023161457 cites W2011974322 @default.
• W2023161457 cites W2016199445 @default.
• W2023161457 cites W2053379248 @default.
• W2023161457 cites W2056543939 @default.
• W2023161457 cites W2084673482 @default.
• W2023161457 cites W2098044998 @default.
• W2023161457 cites W2098458064 @default.
• W2023161457 cites W2107176478 @default.
• W2023161457 cites W2121690051 @default.
• W2023161457 cites W2135706848 @default.
• W2023161457 cites W2141100139 @default.
• W2023161457 cites W2156266070 @default.
• W2023161457 cites W2163815180 @default.
• W2023161457 cites W2230838014 @default.
• W2023161457 cites W2315322366 @default.
• W2023161457 cites W2342319591 @default.
• W2023161457 cites W4376848313 @default.
• W2023161457 doi "https://doi.org/10.1016/j.ahj.2005.01.044" @default.
• W2023161457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16338255" @default.
• W2023161457 hasPublicationYear "2005" @default.
• W2023161457 type Work @default.
• W2023161457 sameAs 2023161457 @default.
• W2023161457 citedByCount "64" @default.
• W2023161457 countsByYear W20231614572012 @default.
• W2023161457 countsByYear W20231614572013 @default.
• W2023161457 countsByYear W20231614572014 @default.
• W2023161457 countsByYear W20231614572015 @default.
• W2023161457 countsByYear W20231614572016 @default.
• W2023161457 countsByYear W20231614572017 @default.
• W2023161457 countsByYear W20231614572018 @default.
• W2023161457 countsByYear W20231614572020 @default.
• W2023161457 countsByYear W20231614572022 @default.
• W2023161457 crossrefType "journal-article" @default.
• W2023161457 hasAuthorship W2023161457A5002556684 @default.
• W2023161457 hasAuthorship W2023161457A5007198463 @default.
• W2023161457 hasAuthorship W2023161457A5017244982 @default.
• W2023161457 hasAuthorship W2023161457A5018419311 @default.
• W2023161457 hasAuthorship W2023161457A5019968582 @default.
• W2023161457 hasAuthorship W2023161457A5039466154 @default.
• W2023161457 hasAuthorship W2023161457A5041291525 @default.
• W2023161457 hasAuthorship W2023161457A5047779930 @default.
• W2023161457 hasAuthorship W2023161457A5057167171 @default.
• W2023161457 hasConcept C126322002 @default.
• W2023161457 hasConcept C141071460 @default.
• W2023161457 hasConcept C164705383 @default.
• W2023161457 hasConcept C168563851 @default.
• W2023161457 hasConcept C204243189 @default.
• W2023161457 hasConcept C2777628954 @default.
• W2023161457 hasConcept C2777785093 @default.
• W2023161457 hasConcept C2777849778 @default.
• W2023161457 hasConcept C2778425758 @default.
• W2023161457 hasConcept C2780400711 @default.
• W2023161457 hasConcept C35294091 @default.
• W2023161457 hasConcept C45393284 @default.
• W2023161457 hasConcept C500558357 @default.
• W2023161457 hasConcept C71924100 @default.
• W2023161457 hasConceptScore W2023161457C126322002 @default.
• W2023161457 hasConceptScore W2023161457C141071460 @default.
• W2023161457 hasConceptScore W2023161457C164705383 @default.
• W2023161457 hasConceptScore W2023161457C168563851 @default.
• W2023161457 hasConceptScore W2023161457C204243189 @default.
• W2023161457 hasConceptScore W2023161457C2777628954 @default.
• W2023161457 hasConceptScore W2023161457C2777785093 @default.
• W2023161457 hasConceptScore W2023161457C2777849778 @default.
• W2023161457 hasConceptScore W2023161457C2778425758 @default.
• W2023161457 hasConceptScore W2023161457C2780400711 @default.
• W2023161457 hasConceptScore W2023161457C35294091 @default.
• W2023161457 hasConceptScore W2023161457C45393284 @default.
• W2023161457 hasConceptScore W2023161457C500558357 @default.
• W2023161457 hasConceptScore W2023161457C71924100 @default.
• W2023161457 hasIssue "6" @default.
• W2023161457 hasLocation W20231614571 @default.
• W2023161457 hasLocation W20231614572 @default.
• W2023161457 hasOpenAccess W2023161457 @default.
• W2023161457 hasPrimaryLocation W20231614571 @default.
• W2023161457 hasRelatedWork W2060202662 @default.
• W2023161457 hasRelatedWork W2144937882 @default.
• W2023161457 hasRelatedWork W2318979957 @default.
• W2023161457 hasRelatedWork W2328099241 @default.

• next